Leerink Partnrs Issues Negative Forecast for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for shares of Hims & Hers Health in a report issued on Tuesday, August 5th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $0.10 per share for the quarter, down from their previous estimate of $0.17. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s FY2026 earnings at $1.04 EPS.

A number of other equities analysts also recently commented on the company. Truist Financial lifted their price objective on Hims & Hers Health from $45.00 to $48.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. UBS Group set a $30.00 price objective on Hims & Hers Health in a research report on Monday, June 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Bank of America upped their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a report on Tuesday, April 29th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $39.83.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $51.05 on Thursday. Hims & Hers Health has a one year low of $13.47 and a one year high of $72.98. The company has a market cap of $11.43 billion, a price-to-earnings ratio of 63.81, a PEG ratio of 2.16 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.32 and a current ratio of 4.98. The business’s 50 day moving average price is $53.76 and its 200 day moving average price is $44.79.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The company had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same quarter in the prior year, the firm earned $0.06 earnings per share. The company’s revenue for the quarter was up 72.6% on a year-over-year basis.

Institutional Trading of Hims & Hers Health

Hedge funds have recently modified their holdings of the stock. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the second quarter valued at $29,000. Bessemer Group Inc. raised its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter valued at $30,000. UMB Bank n.a. raised its stake in shares of Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after acquiring an additional 933 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Hims & Hers Health in the first quarter valued at $41,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of the business’s stock in a transaction on Monday, July 14th. The stock was sold at an average price of $47.70, for a total value of $552,413.70. Following the sale, the chief financial officer owned 54,084 shares in the company, valued at approximately $2,579,806.80. The trade was a 17.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Chi sold 2,100 shares of the business’s stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total value of $120,792.00. Following the completion of the sale, the insider owned 278,654 shares in the company, valued at $16,028,178.08. This represents a 0.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 737,704 shares of company stock worth $40,644,035 over the last quarter. 13.71% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.